Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $23.00.

Several equities research analysts recently commented on IOVA shares. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. UBS Group began coverage on shares of Iovance Biotherapeutics in a research report on Thursday, October 24th. They issued a "buy" rating and a $17.00 price objective on the stock.

Insider Transactions at Iovance Biotherapeutics

In other news, Director Ryan D. Maynard sold 50,000 shares of the business's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $10.06, for a total transaction of $503,000.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at $75,450. The trade was a 86.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. ORG Wealth Partners LLC acquired a new position in Iovance Biotherapeutics in the 3rd quarter valued at about $89,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Iovance Biotherapeutics by 31.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,978 shares of the biotechnology company's stock worth $105,000 after acquiring an additional 2,624 shares in the last quarter. Impact Partnership Wealth LLC acquired a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $83,000. Clear Creek Financial Management LLC acquired a new stake in Iovance Biotherapeutics in the fourth quarter valued at approximately $91,000. Finally, KBC Group NV boosted its position in Iovance Biotherapeutics by 105.7% in the fourth quarter. KBC Group NV now owns 12,303 shares of the biotechnology company's stock valued at $91,000 after buying an additional 6,321 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company's stock.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ IOVA traded down $0.11 during midday trading on Monday, reaching $6.15. 5,622,875 shares of the stock were exchanged, compared to its average volume of 9,500,588. The business has a 50-day simple moving average of $7.63 and a two-hundred day simple moving average of $9.11. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -4.12 and a beta of 0.57. Iovance Biotherapeutics has a 12 month low of $5.57 and a 12 month high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03. The business had revenue of $58.56 million for the quarter, compared to analysts' expectations of $53.54 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. During the same period in the previous year, the firm posted ($0.46) EPS. Equities research analysts expect that Iovance Biotherapeutics will post -1.23 earnings per share for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.